No Data
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
B.Riley Financial analyst Mayank Mamtani maintains $Vaxart(VXRT.US)$ with a buy rating, and maintains the target price at $2.5.According to TipRanks data, the analyst has a success rate of 27.3% and
Buy Rating Affirmed for Vaxart Amidst Promising Norovirus Vaccine Developments and Market Opportunity
Individual Investors Who Own 59% Along With Institutions Invested in Vaxart, Inc. (NASDAQ:VXRT) Saw Increase in Their Holdings Value Last Week
While Institutions Invested in Vaxart, Inc. (NASDAQ:VXRT) Benefited From Last Week's 23% Gain, Retail Investors Stood to Gain the Most
Vaxart(VXRT.US) Director Buys US$13,578 in Common Stock
$Vaxart(VXRT.US)$ Director Watson W. Mark purchased 20,000 shares of common stock on Jun 18, 2024 at an average price of $0.6789 for a total value of $13,578.Source: Announcement What is statement of
12 Health Care Stocks Moving In Wednesday's Intraday Session
No Data